Wijkstrom Joakim 4

What Happened
Joakim Wijkstrom, Senior Vice President and Chief Marketing Officer of Vanda Pharmaceuticals (VNDA), received a grant of 125,000 restricted stock units (RSUs) on February 18, 2026 (transaction code A — award/grant). The RSUs were granted for no cash consideration (grant price reported as $0.00). This is a compensation award, not a market purchase or sale.

Key Details

• Transaction date: 2026-02-18; filing date: 2026-02-19 (Form 4 accession 0001193125-26-059792).
• Award: 125,000 RSUs; grant price: $0.00 (no cash paid).
• Vesting: RSUs vest in four equal annual installments; first vesting on March 1, 2027, subject to continued employment. Vested shares will be delivered on the First Permissible Trading Day on or after each vesting date (per footnote).
• Shares owned after transaction: not disclosed in the filing.
• No 10b5-1 plan, tax-withholding detail, or late-filing flag is noted in the public filing.

Context
RSUs are time-based equity awards that convert to shares only if vesting conditions (here, continued employment) are met; they are a form of compensation rather than an immediate buy/sell signal. Retail investors typically treat grants as management compensation — informative about pay structure and potential future share dilution when RSUs vest and are delivered.